The diversity of these diseases and their numerous new treatment options require corresponding experience. For this reason, we treat myeloma patients several times a week in our special consultation hours and discuss the examination results at our interdisciplinary hemato-oncological tumor board in order to determine the best therapy in each case.
The therapeutic spectrum includes, among other things:
- Modern targeted drug therapy such as proteasome inhibitors, immunomodulating substances and conventional chemotherapies, individually and in combination
- Immunotherapies against surface structures of myeloma cells
- High-dose therapies with subsequent autologous (patient’s own) blood stem cell transplantation
- Allogeneic related or unrelated blood stem cell transplantation
